GRAY Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (20 Mar 2023 @ 16:00):

Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve...

Stats
Today's Volume	24 628.00
Average Volume	5 277.00
Market Cap	120.98M
EPS	$0 ( 2024-03-06 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.267
ATR14	$0.618 (22.89%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-11	Wilson Robert N	Buy	506	Common Stock
2023-11-07	Leheny A. Rachel	Buy	2 000	Common Stock
2023-11-06	Roberts Eric W	Buy	2 400	Common Stock
2023-11-03	Roberts Eric W	Buy	11 249	Common Stock
2023-11-03	Roberts Eric W	Buy	3 700	Common Stock

INSIDER POWER
96.28
Last 97 transactions
Buy: 3 103 303 \| Sell: 60 672

Volume Correlation

Long: -0.13 (neutral)

Short: 0.37 (neutral)

Signal:(40.58) Neutral

Graybug Vision, Inc. Correlation

10 Most Positive Correlations
INFI	0.939
POWW	0.935
VSTA	0.931
TTCF	0.926
NOTV	0.925
JWEL	0.924
ACET	0.918
COMT	0.917
TCDA	0.915
VCSA	0.91

10 Most Negative Correlations
IMMR	-0.919
CCRC	-0.918
IBEX	-0.899
PBFS	-0.89
MGI	-0.883
ISIG	-0.878
ACLX	-0.875
SEDG	-0.873
MSON	-0.866
ARNA	-0.851

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Graybug Vision, Inc. Correlation - Currency/Commodity

0.63
( weak )

0.59
( weak )

-0.68
( moderate negative )

0.22
( neutral )

-0.32
( neutral )

0.04
( neutral )

Graybug Vision, Inc. Financials

Annual	2022
Revenue:	$2.96M
Gross Profit:	$2.96M (100.00 %)
EPS:	$-319.50

Q3	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$0

Q2	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$0

Q1	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-15.88

Financial Reports:

No articles found.

Graybug Vision, Inc.

Graybug Vision, Inc., a clinical-stage biopharmaceutical company, focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. It also develops GB-102, for the treatment of diabetic retinopathy; and GB-401, an intravitreally injected implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was incorporated in 2011 and is based in Redwood City, California.